A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment
Public ClinicalTrials.gov record NCT03069365. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Renally-Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (EXPEDITION-5)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a Phase 3b, open-label, non-randomized, multicenter study to evaluate the efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) in participants with chronic hepatitis C virus (HCV) genotype (GT) 1 - 6 infection without liver cirrhosis or with compensated liver cirrhosis and with chronic renal impairment in participants who were either HCV treatment-naïve (TN) or prior treatment-experienced (TE) with interferon (IFN) or pegylated interferon (PegIFN) with or without ribavirin (RBV), or sofosbuvir (SOF) plus RBV with or without pegIFN.
Study identification
- NCT ID
- NCT03069365
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 101 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 27, 2017
- Primary completion
- Feb 19, 2018
- Completion
- Jun 4, 2018
- Last update posted
- Mar 3, 2019
2017 – 2018
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Scripps Clinic /ID# 159116 | La Jolla | California | 92037 | — |
| Huntington Medical Foundation /ID# 160653 | Pasadena | California | 91105 | — |
| Tampa General Medical Group /ID# 159115 | Tampa | Florida | 33606 | — |
| Northwest Louisiana Nephrology /ID# 160652 | Shreveport | Louisiana | 71101 | — |
| Massachusetts General Hospital /ID# 159114 | Boston | Massachusetts | 02114 | — |
| North Shore University Hospital /ID# 159108 | New Hyde Park | New York | 11040 | — |
| Columbia Univ Medical Center /ID# 159112 | New York | New York | 10032-3725 | — |
| Carolinas Medical Center /ID# 159113 | Charlotte | North Carolina | 28203 | — |
| University of Pennsylvania /ID# 159117 | Philadelphia | Pennsylvania | 19104-5502 | — |
| Thomas Jefferson University /ID# 159754 | Philadelphia | Pennsylvania | 19107-4414 | — |
| TX Liver Inst, Americ Res Corp /ID# 159111 | San Antonio | Texas | 78215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03069365, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 3, 2019 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03069365 live on ClinicalTrials.gov.